Technology Bundle ID: TAB-2696

Novel Rift Valley Fever Virus Vaccines

Request More Info
Licensing Contact:
Primary Inventors: 
Brian Bird (CDC)
Cesar Albarino (CDC), Stuart Nichol (CDC), Thomas Ksiazek (CDC)
Development Stage: 
Pre-clinical (in vivo)
Development Status: 
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 

This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses.

  • Rift Valley fever (RVF) virus vaccine development or improvement
  • Prevention of RVF virus infection in livestock and humans
  • Biodefense, biosecurity
  • In vivo evidence shows single-dose protection
  • Allows for discrimination between vaccinated and naturally-infected subjects
  • Useful for controlled screening of therapeutic compounds


PCT Application PCT/US2008/087023
Filed on 2008-12-16
US Pat 10,064,933

Issued 2018-09-04
US Pat 8,673,629

Issued 2014-03-18
US Pat 9,439,935

Issued 2016-09-13

Additional applications granted and pending


Bird BH, et al.
PMID 18199647
CDC Fact Sheet: Rift Valley Fever


Dec 23, 2013

Data Source: